Pyrludimide (KX-826) or Breezula (clascoterone) Treatment 3/25/2026
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
View this post in the Community โ
Similar Community Posts Join
5 / 73 resultscommunity Why so much hate for PP405 all of a sudden?
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
community Do you believe there will be a game changing treatment in the next 10 years?
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stem cells as promising options, while others express doubt due to past disappointments and lack of focused research.
community What to look Forward to in 2025
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
community Anyone else crying themselves to sleep because of the pyrilutamide fail?
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
community Pyrilutamide PHASE 2 Results just one months to go. Are you excited???๐คฉ
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
Related Research
0 / 0 results — no results